- Trials with a EudraCT protocol (248)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
248 result(s) found for: Initiation factors.
Displaying page 1 of 13.
EudraCT Number: 2005-003617-33 | Sponsor Protocol Number: 03-2005 | Start Date*: Information not available in EudraCT |
Sponsor Name:Charité | ||
Full Title: A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze | ||
Medical condition: actinic keratosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003775-30 | Sponsor Protocol Number: CICL670ABE04 | Start Date*: 2016-01-18 |
Sponsor Name:Novartis Pharma NV | ||
Full Title: A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in... | ||
Medical condition: The study will include two groups of patients with low and intermediate 1 risk myelodysplastic syndrome. One group consists of patients who experience an hematological response while on deferasirox... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-000044-25 | Sponsor Protocol Number: 1143-201 | Start Date*: 2013-07-16 | |||||||||||
Sponsor Name:Debiopharm S.A. | |||||||||||||
Full Title: A Phase I/II randomized study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio1143 combined with concurrent Chemo-Radiation Therapy in patients with... | |||||||||||||
Medical condition: Patients with locally advanced squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000882-11 | Sponsor Protocol Number: NEORAD | Start Date*: 2011-08-16 |
Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie ) | ||
Full Title: A comparison of blood and tissue biomarkers before and after nephrectomy in the firstline setting with everolimus in patients with locally advanced or metastatic renal cell carcinoma | ||
Medical condition: locally advanced or metastatic renal cell carcinoma - 1st line | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005001-78 | Sponsor Protocol Number: KLI148-B00 | Start Date*: 2012-01-26 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie u. Psychotherapie, Abteil. für biologische Psychiatrie | ||
Full Title: Neural Correlates of SSRI Drug Response: Impact of Stress System Genes | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003189-29 | Sponsor Protocol Number: ONCO-01-2017 | Start Date*: 2018-02-09 | |||||||||||
Sponsor Name:L'Institut Mutualiste Montsouris | |||||||||||||
Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer | |||||||||||||
Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001627-40 | Sponsor Protocol Number: FLE-007 | Start Date*: 2022-06-07 | |||||||||||
Sponsor Name:InCarda Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm | |||||||||||||
Medical condition: Recent-onset symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003835-28 | Sponsor Protocol Number: APHP210089 | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS | |||||||||||||
Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO | |||||||||||||
Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002461-66 | Sponsor Protocol Number: CABL001A2301 | Start Date*: 2017-10-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyro... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Ongoing) BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) BE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005109-19 | Sponsor Protocol Number: ATTICUS | Start Date*: 2015-11-10 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Apixaban for treatment of embolic stroke of undetermined source | ||
Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000414-16 | Sponsor Protocol Number: APHP-200040 | Start Date*: 2021-11-23 | |||||||||||
Sponsor Name:APHP | |||||||||||||
Full Title: Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-NOT trial”. A prospective, randomized, double blinded, mul... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003309-88 | Sponsor Protocol Number: ROR-PH-302 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He... | |||||||||||||
Medical condition: pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001802-30 | Sponsor Protocol Number: TMP-3001-2020-30 | Start Date*: 2021-10-28 |
Sponsor Name:Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP) | ||
Full Title: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma) | ||
Medical condition: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002940-26 | Sponsor Protocol Number: 212082PCR3011 | Start Date*: 2013-05-24 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me... | |||||||||||||
Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003336-59 | Sponsor Protocol Number: 211038 | Start Date*: 2023-01-13 |
Sponsor Name:APHP | ||
Full Title: Efficacy and Safety of Obinutuzumab versus Rituximab in childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : a double-blind multicenter randomized controlled study | ||
Medical condition: Idiopathic nephrotic syndrome (INS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000899-15 | Sponsor Protocol Number: EORTC-1531-ROG | Start Date*: 2019-12-03 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study | |||||||||||||
Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005036-28 | Sponsor Protocol Number: 2012/41 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:CENTRE ANTOINE LACASSAGNE | |||||||||||||
Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate | |||||||||||||
Medical condition: Prostate cancer metastatic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006177-88 | Sponsor Protocol Number: FARM65KNKY | Start Date*: 2008-01-24 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A randomized controlled trial of alteplase (rt-PA) vs standard treatment in acute ischemic hemispheric stroke in patients aged more than 80 years where thrombolysis is initiated within 3 hours afte... | |||||||||||||
Medical condition: acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001752-17 | Sponsor Protocol Number: PI20208430039 | Start Date*: 2020-05-13 |
Sponsor Name:CHU Amiens Picardie | ||
Full Title: Proactive Management of Outpatient Covid-19 Patients : a randomised controlled trial | ||
Medical condition: Infection SARS-CoV-2 | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004447-36 | Sponsor Protocol Number: ZonMw848015005 | Start Date*: 2017-06-23 |
Sponsor Name:Stichting Rotterdams Onderzoeksconsortium Kindergeneeskunde | ||
Full Title: INTRAVENOUS-TO-ORAL ANTIBIOTIC SWITCH THERAPY FOR SUSPECTED NEONATAL BACTERIAL INFECTIONS: CLINICAL EFFICACY, SAFETY AND COST-EFFECTIVENESS | ||
Medical condition: Neonatal probable bacterial infection | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
